An adjuvanted SARS-CoV-2 RBD nanoparticle elicits neutralizing antibodies and fully protective immunity in aged mice

Article activity feed

1. 

   ScreenIT

   Sep 12, 2021

   SciScore for 10.1101/2021.09.09.459664: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Ethics	IACUC: Mice were housed under specific pathogen-free conditions at Boston Children’s Hospital, and all procedures were approved under the Institutional Animal Care and Use Committee (IACUC) and operated under the supervision of the Department of Animal Resources at Children’s Hospital (ARCH) (Protocol number 19-02-3897R).
   Sex as a biological variable	Animals: Female, 3 month old BALB/c and C57BL/6J mice were purchased from Jackson Laboratory (Bar Harbor, ME), and CD-1 mice were purchased from Charles River Laboratories (Wilmington, MA).
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Experimental Models: Cell Lines
   S…

   SciScore for 10.1101/2021.09.09.459664: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Ethics	IACUC: Mice were housed under specific pathogen-free conditions at Boston Children’s Hospital, and all procedures were approved under the Institutional Animal Care and Use Committee (IACUC) and operated under the supervision of the Department of Animal Resources at Children’s Hospital (ARCH) (Protocol number 19-02-3897R).
   Sex as a biological variable	Animals: Female, 3 month old BALB/c and C57BL/6J mice were purchased from Jackson Laboratory (Bar Harbor, ME), and CD-1 mice were purchased from Charles River Laboratories (Wilmington, MA).
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Experimental Models: Cell Lines
   Sentences	Resources
   The sample/virus mixture was then incubated at 37°C (5.0% CO2) for 1 hour before transferring 100 μl to 96-well titer plates with 5e3 VeroE6 cells.	VeroE6 suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)
   luciferase reporter plasmid pLenti-CMV Puro-Luc (Addgene), and spike protein expressing pcDNA3.1-SARS CoV-2 SΔCT of variants were co-transfected into HEK293T cells by lipofectamine 2000 (ThermoFisher).	HEK293T suggested: None
   To determine the neutralization activity of the plasma or serum samples from participants, HEK293T-hACE2 cells were seeded in 96-well tissue culture plates at a density of 1.75 × 104 cells/well overnight.	HEK293T-hACE2 suggested: RRID:CVCL_A7UK)
   Experimental Models: Organisms/Strains
   Sentences	Resources
   Animals: Female, 3 month old BALB/c and C57BL/6J mice were purchased from Jackson Laboratory (Bar Harbor, ME), and CD-1 mice were purchased from Charles River Laboratories (Wilmington, MA).	BALB/c suggested: None C57BL/6J suggested: RRID:IMSR_JAX:000664) CD-1 suggested: RRID:MGI:2686808)
   Recombinant DNA
   Sentences	Resources
   Briefly, the packaging plasmid psPAX2 (AIDS Resource and Reagent Program)	psPAX2 suggested: RRID:Addgene_12260)
   luciferase reporter plasmid pLenti-CMV Puro-Luc (Addgene), and spike protein expressing pcDNA3.1-SARS CoV-2 SΔCT of variants were co-transfected into HEK293T cells by lipofectamine 2000 (ThermoFisher).	pLenti-CMV Puro-Luc suggested: None pcDNA3.1-SARS suggested: None
   Software and Algorithms
   Sentences	Resources
   Each sample was measured in triplicate, and the intensity of the size distribution was plotted in GraphPad Prism 9 (GraphPad Software)	GraphPad suggested: (GraphPad Prism, RRID:SCR_002798)
   Briefly, the packaging plasmid psPAX2 (AIDS Resource and Reagent Program)	AIDS Resource and Reagent Program suggested: None
   SARS-CoV-2 lung titers were quantified by homogenizing harvested lungs in PBS (Quality Biological Inc.) using 1.0 mm glass beads (Sigma Aldrich) and a Beadruptor (Omni International Inc.).	Quality Biological suggested: None
   Statistical analysis: Statistical analyses were performed using Prism v9.0.2 (GraphPad Software).	Prism suggested: (PRISM, RRID:SCR_005375)

   ---

   Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

   ---

   Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

   ---

   Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
   

   Identifier	Status	Title
   NCT04750343	Active, not recruiting	Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle V…
   NCT04742738	Active, not recruiting	Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle V…

   ---

   Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

   ---

   Results from JetFighter: We did not find any issues relating to colormaps.

   ---

   Results from rtransparent:

   • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
   • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
   • No protocol registration statement was detected.

   ---

   Results from scite Reference Check: We found no unreliable references.

   ---

   Read the original source
2. 

   Version published to 10.1101/2021.09.09.459664 on bioRxiv

   Sep 9, 2021